Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Universal Vision Biotechnology Co., Ltd. (3218:TWSE), powered by AI.
Universal Vision Biotechnology Co., Ltd. is currently trading at $134.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Universal Vision Biotechnology Co., Ltd. on Alpha Lenz.
View Universal Vision Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.
“Universal Vision Biotechnology Co., Ltd.'s ROE is 27.3%. Explore profitability and growth together.”
Ask for details →Universal Vision Biotechnology Co., Ltd. is a healthcare company specializing in eye care services and optical products. The firm operates a chain of eye care clinics in Taiwan and China, providing comprehensive ophthalmic services, optometric consultations, and hospital management solutions. Its product portfolio includes optical devices, eyeglasses, prescription lenses, sunglasses, and a range of contact lenses addressing myopia, hyperopia, presbyopia, and astigmatism. The company also offers leasing of medical equipment, technical consultancy, and medical cosmetology services such as eye plastic and micro cosmetic surgery. Serving both medical and consumer needs, Universal Vision Biotechnology Co., Ltd. plays a significant role in the region’s healthcare sector, contributing to advancements in vision correction and eye health through its medical operations and optical retail business. Headquartered in Taipei and founded in the early 1990s, it has established itself as a key provider in the medical equipment and healthcare services industry, supporting eye health across a broad demographic spectrum.
“Universal Vision Biotechnology Co., Ltd.'s ROE is 27.3%. Explore profitability and growth together.”
Ask for details →Universal Vision Biotechnology Co., Ltd. (ticker: 3218) is a company listed on TWSE in the Healthcare sector (Medical Care Facilities).
The current price is 134 with a P/E ratio of -x and P/B of -x.
ROE is 27.28% and operating margin is 32.76%. Annual revenue is $4.2B.